Azithromycin suppresses P. gingivalis LPS-induced pro-inflammatory cytokine and chemokine production by human gingival fibroblasts in vitro

Clinical Oral Investigations

Volumn 19, Issue 2, 2015, Pages 221-227

  Doyle, C J ^a   Fitzsimmons, T R ^a   Marchant, C ^a   Dharmapatni, A A S S K ^a   Hirsch, R ^a   Bartold, P M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Azithromycin; Infection; Inflammation; Periodontitis

Indexed keywords

AUTACOID; AZITHROMYCIN; CHEMOKINE; CYTOKINE;

BIOSYNTHESIS; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GINGIVA; HUMAN; METABOLISM; MICROBIOLOGY; PORPHYROMONAS GINGIVALIS;

AZITHROMYCIN; CHEMOKINES; CYTOKINES; FIBROBLASTS; GINGIVA; HUMANS; INFLAMMATION MEDIATORS; PORPHYROMONAS GINGIVALIS;

EID: 84939884925     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-014-1249-7     Document Type: Article

References (39)

1. Di Benedetto A, Gigante I, Colucci S, Grano M (2013) Periodontal disease: linking the primary inflammation to bone loss. Clin Dev Immunol 2013:503754
2. Greenstein G (1992) Periodontal response to mechanical non-surgical therapy: a review. J Periodontol 63:118–130
3. Drisko CH (2001) Nonsurgical periodontal therapy. Periodontol 2000(25):77–88
4. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T (2007) Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol 78:422–429
5. Heitz-Mayfield LJ (2009) Systemic antibiotics in periodontal therapy. Aust Dent J 54(Suppl 1):S96–S101
6. Preshaw PM (2008) Host response modulation in periodontics. Periodontol 2000(48):92–110
7. Pajukanta R (1993) In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 8:325–326
8. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H (1992) In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 36:1241–1243
9. Bartold PM, du Bois AH, Gannon S, Haynes DR, Hirsch RS (2013) Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis. Inflammopharmacology 21:321–338
10. Hirsch R, Deng H, Laohachai MN (2012) Azithromycin in periodontal treatment: more than an antibiotic. J Periodontal Res 47:137–148
11. Muniz FW, de Oliveira CC, de Sousa CR, Moreira MM, de Moraes ME, Martins RS (2013) Azithromycin: a new concept in adjuvant treatment of periodontitis. Eur J Pharmacol 705:135–139
12. Hirsch R (2010) Periodontal healing and bone regeneration in response to azithromycin. Aust Dent J 55:193–199
13. Schmidt EF, Bretz WA (2007) Benefits of additional courses of systemic azithromycin in periodontal disease case report. N Y State Dent J 73:40–45
14. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG (2011) Immunomodulatory effects of macrolide antibiotics—part 1: biological mechanisms. Respir Int Rev Thorac Dis 81:67–74
15. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, Sugiyama Y (1987) Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25:632–642
16. Bartold PM, Van Dyke TE (2013) Periodontitis: a host-mediated disruption of microbial homeostasis. Unlearning learned concepts. Periodontol 2000(62):203–217
17. Kamemoto A, Ara T, Hattori T, Fujinami Y, Imamura Y, Wang PL (2009) Macrolide antibiotics like azithromycin increase lipopolysaccharide-induced IL-8 production by human gingival fibroblasts. Eur J Med Res 14:309–314
18. Gannon SC, Cantley MD, Haynes DR, Hirsch R, Bartold PM (2013) Azithromycin suppresses human osteoclast formation and activity in vitro. J Cell Physiol 228:1098–1107
19. Takashiba S, Naruishi K, Murayama Y (2003) Perspective of cytokine regulation for periodontal treatment: fibroblast biology. J Periodontol 74:103–110
20. Scheres N, Laine ML, de Vries TJ, Everts V, van Winkelhoff AJ (2010) Gingival and periodontal ligament fibroblasts differ in their inflammatory response to viable Porphyromonas gingivalis. J Periodontal Res 45:262–270
21. Morandini AC, Sipert CR, Gasparoto TH, Greghi SL, Passanezi E, Rezende ML, Sant’ana AP, Campanelli AP, Garlet GP, Santos CF (2010) Differential production of macrophage inflammatory protein-1alpha, stromal-derived factor-1, and IL-6 by human cultured periodontal ligament and gingival fibroblasts challenged with lipopolysaccharide from P. gingivalis. J Periodontol 81:310–317
22. Ara T, Kurata K, Hirai K, Uchihashi T, Uematsu T, Imamura Y, Furusawa K, Kurihara S, Wang PL (2009) Human gingival fibroblasts are critical in sustaining inflammation in periodontal disease. J Periodontal Res 44:21–27
23. Jonsson D, Amisten S, Bratthall G, Holm A, Nilsson BO (2009) LPS induces GROalpha chemokine production via NF-kappaB in oral fibroblasts. Inflamm Res 58:791–796
24. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T et al (1990) IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297–3303
25. Wada N, Maeda H, Yoshimine Y, Akamine A (2004) Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35:629–635
26. Mogi M, Otogoto J, Ota N, Inagaki H, Minami M, Kojima K (1999) Interleukin 1 beta, interleukin 6, beta 2-microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human periodontal disease. Arch Oral Biol 44:535–539
27. Fitzsimmons TR, Sanders AE, Slade GD, Bartold PM (2009) Biomarkers of periodontal inflammation in the Australian adult population. Aust Dent J 54:115–122
28. Yu X, Graves DT (1995) Fibroblasts, mononuclear phagocytes, and endothelial cells express monocyte chemoattractant protein-1 (MCP-1) in inflamed human gingiva. J Periodontol 66:80–88
29. Wang PL, Ohura K, Fujii T, Oido-Mori M, Kowashi Y, Kikuchi M, Suetsugu Y, Tanaka J (2003) DNA microarray analysis of human gingival fibroblasts from healthy and inflammatory gingival tissues. Biochem Biophys Res Commun 305:970–973
30. Wada N, Wang B, Lin NH, Laslett AL, Gronthos S, Bartold PM (2011) Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. J Periodontal Res 46:438–447
31. Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, Ohshima T, Maeda N, Arai T (2007) Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 78:918–923
32. Lai PC, Ho W, Jain N, Walters JD (2011) Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration. J Periodontol 82:1582–1586
33. Malizia T, Tejada MR, Ghelardi E, Senesi S, Gabriele M, Giuca MR, Blandizzi C, Danesi R, Campa M, Del Tacca M (1997) Periodontal tissue disposition of azithromycin. J Periodontol 68:1206–1209
34. Chou CH, Walters JD (2008) Clarithromycin transport by gingival fibroblasts and epithelial cells. J Dent Res 87:777–781
35. Ho W, Eubank T, Leblebicioglu B, Marsh C, Walters J (2010) Azithromycin decreases crevicular fluid volume and mediator content. J Dent Res 89:831–835
36. Matsumura Y, Mitani A, Suga T, Kamiya Y, Kikuchi T, Tanaka S, Aino M, Noguchi T (2011) Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide. J Periodontol 82:1623–1631
37. Zhou J, Windsor LJ (2007) Heterogeneity in the collagen-degrading ability of Porphyromonas gingivalis-stimulated human gingival fibroblasts. J Periodontal Res 42:77–84
38. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R (1987) Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 31:1939–1947
39. Bartold PM, Narayanan AS (2006) Molecular and cell biology of healthy and diseased periodontal tissues. Periodontol 2000(40):29–49